These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35979208)

  • 21. Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series.
    Wang Z; Wang Y; Wang S; Ran Q; Peng S; Zhang Y; Zhang J; Zhang D; Wang L; Lan W; Liu Q; Jiang J
    Ann Med Surg (Lond); 2024 Jan; 86(1):245-251. PubMed ID: 38222740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients.
    Rehme C; Fritsch B; Thomas L; Istin S; Burchert C; Hummel B; Baleanu-Curaj B; Reis H; Szarvas T; Ruebben H; Hadaschik B; Niedworok C
    Int Urol Nephrol; 2022 Jan; 54(1):71-79. PubMed ID: 34817753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
    van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
    World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
    Briganti A; Gandaglia G; Scuderi S; Gallina A; Colombo R; Fossati N; Barletta F; Pellegrino A; Nocera L; Montorsi F; Necchi A
    Eur Urol; 2020 May; 77(5):576-580. PubMed ID: 31911010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
    van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
    PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018).
    González Del Alba A; De Velasco G; Lainez N; Maroto P; Morales-Barrera R; Muñoz-Langa J; Pérez-Valderrama B; Basterretxea L; Caballero C; Vazquez S
    Clin Transl Oncol; 2019 Jan; 21(1):64-74. PubMed ID: 30565086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
    Lee DH; Jeong JY; Song W
    Onco Targets Ther; 2021; 14():845-855. PubMed ID: 33574678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review.
    König F; Pradere B; Grossmann NC; Quhal F; Rajwa P; Laukhtina E; Mori K; Katayama S; Yanagisawa T; Mostafai H; Motlagh RS; Aydh A; Dahlem R; Shariat SF; Rink M
    Transl Cancer Res; 2022 Apr; 11(4):908-917. PubMed ID: 35571640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
    Hwang EC; Sathianathen NJ; Imamura M; Kuntz GM; Risk MC; Dahm P
    Cochrane Database Syst Rev; 2019 May; 5(5):CD013336. PubMed ID: 31111956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy.
    Smith ZL; Christodouleas JP; Keefe SM; Malkowicz SB; Guzzo TJ
    BJU Int; 2013 Jul; 112(1):13-25. PubMed ID: 23356411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
    Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer.
    Russell CM; Lebastchi AH; Borza T; Spratt DE; Morgan TM
    Bladder Cancer; 2016 Oct; 2(4):381-394. PubMed ID: 28035319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.
    Li K; Zhong W; Fan J; Wang S; Yu D; Xu T; Lyu J; Wu S; Qin T; Wu Z; Xu L; Wu K; Liu Z; Hu Z; Li F; Wang J; Wang Q; Min J; Zhang Z; Yu L; Ding S; Huang L; Zhao T; Huang J; Lin T
    Nat Cancer; 2024 Oct; 5(10):1465-1478. PubMed ID: 39256488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perioperative immunotherapy in muscle-invasive bladder cancer.
    Lee HH; Ham WS
    Transl Cancer Res; 2020 Oct; 9(10):6546-6553. PubMed ID: 35117264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra-arterial chemotherapy for muscle-invasive bladder cancer following transurethral resection.
    Liang S; Zou Q; Han B; Jing Y; Cui D; An X; Gao Y; Hu J; Xia S
    Urol Int; 2015; 94(4):406-11. PubMed ID: 25678415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?
    Pederzoli F; Bandini M; Marandino L; Raggi D; Giannatempo P; Salonia A; Gallina A; Briganti A; Montorsi F; Necchi A
    Eur Urol Oncol; 2021 Dec; 4(6):1006-1010. PubMed ID: 32847746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Becker REN; Meyer AR; Brant A; Reese AC; Biles MJ; Harris KT; Netto G; Matoso A; Hoffman-Censits J; Hahn NM; Choi W; McConkey D; Pierorazio PM; Johnson MH; Schoenberg MP; Kates MR; Baras A; Bivalacqua TJ
    Eur Urol; 2021 Mar; 79(3):364-371. PubMed ID: 32814637
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.